| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/27/2005 | EP1225814B1 Fibrous-liponutritional complexes and compositions containing them |
| 04/27/2005 | EP1217993B1 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/27/2005 | EP1135153B1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 04/27/2005 | EP1105122B1 Pharmaceutical compositions containing lipase inhibitors |
| 04/27/2005 | EP1033997B1 Method of mobilizing hematopoietic stem cells |
| 04/27/2005 | EP1011651B1 Method of treating diabetes and related disease states |
| 04/27/2005 | EP0942733B1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 04/27/2005 | EP0918515B1 USE OF INHIBITORS OF THE CELLULAR Na+ /H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS |
| 04/27/2005 | EP0873519A4 Hiv protease inhibitors |
| 04/27/2005 | EP0833651B1 Analgesic use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
| 04/27/2005 | CN1610755A Methods of profiling gene expression, protein or metabolite levels |
| 04/27/2005 | CN1610751A Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 04/27/2005 | CN1610696A Antibodies that immunospecifically bind to TRAIL receptors |
| 04/27/2005 | CN1610695A Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 04/27/2005 | CN1610676A Compounds and method for the treatment of overactive bladder |
| 04/27/2005 | CN1610567A Enhanced systemic absorption of intradermally delivered substances |
| 04/27/2005 | CN1610564A Compositions and methods of using collajolie |
| 04/27/2005 | CN1610559A Prostaglandin composition for the treatment of erectile dysfunction |
| 04/27/2005 | CN1610558A Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification |
| 04/27/2005 | CN1610557A 6-fluorobicyclo 3.1.0 hexane derivatives |
| 04/27/2005 | CN1610548A Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension |
| 04/27/2005 | CN1610546A 病毒聚合酶抑制剂 Viral polymerase inhibitor |
| 04/27/2005 | CN1610545A Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 04/27/2005 | CN1610543A Use of N, N-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy |
| 04/27/2005 | CN1610542A New use for the treatment of gastroesophageal reflux disease |
| 04/27/2005 | CN1610536A Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis |
| 04/27/2005 | CN1609206A Crystal structure of oxidosqualene cyclase |
| 04/27/2005 | CN1609197A High-yield reverse immunization for finding tumor specific antigen and tumor specific antigen determinant |
| 04/27/2005 | CN1609196A High-yield T lymphocyte cloning technology for finding tumor specific antigen and tumor specific antigen determinant |
| 04/27/2005 | CN1198936C Alzheimer's disease secretase |
| 04/27/2005 | CN1198932C Streptococcus pneumoniae antigens |
| 04/27/2005 | CN1198931C MOraxella catarrhalis BASB034 polypeptides and uses thereof |
| 04/27/2005 | CN1198817C N-(imidazolylalkyl) substituted cyclic amines as histamine-H3 agonists or antagonists |
| 04/27/2005 | CN1198651C Composition comprising tramadol material and anticonvulsant drug |
| 04/27/2005 | CN1198649C Drug composition containing PGD2 antagonists for curing inhibitor |
| 04/27/2005 | CN1198628C Conditioned cell culture medium compositions and method of use |
| 04/27/2005 | CN1198626C Method and system for production and collection of lavage induced stool (LIS) for chemical and biologic tests of cells |
| 04/27/2005 | CN1198624C Oligosaccharide mixture |
| 04/27/2005 | CN1198605C Compound with 5-HT1A activity useful for treating disorders of outer retina |
| 04/27/2005 | CN1198597C Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor |
| 04/27/2005 | CN1198594C Therapeutically active compositions |
| 04/27/2005 | CN1198592C Process for producing particles with converted amorphous and/or meta-stable drystalline region into crystalline state |
| 04/27/2005 | CN1198589C Method for controlling liposome size |
| 04/27/2005 | CN1198576C Skin care compositions contg. combination of skin care actives |
| 04/27/2005 | CN1198563C Acidified composition for topical treatment of nail and skin conditions |
| 04/26/2005 | US6884809 Method and compositions for reducing cardiac dysfunctions with a selective histamine H3 receptor agonist |
| 04/26/2005 | US6884804 Inhibitors of Src and other protein kinases |
| 04/26/2005 | US6884803 Phenylalkynes |
| 04/26/2005 | US6884792 Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions |
| 04/26/2005 | US6884784 Diagnosis and management of infection caused by chlamydia |
| 04/26/2005 | US6884782 Amino acid containing compounds useful as modulators of the immune system |
| 04/26/2005 | US6884773 Modified hemoglobins, including nitrosylhemoglobins, and uses thereof |
| 04/26/2005 | US6884772 Administering endothelins or agonists as drugs or cosmetics for hair removal or wool harvesting |
| 04/26/2005 | US6884769 Administering enzyme inhibitors or cell growth regulators for prophylaxis of bone disorders |
| 04/26/2005 | US6884768 Using taurine compound; adjust bioavailability; prevent, suppression damage to intestine mucous membrane |
| 04/26/2005 | US6884575 Diagnosis and treatment of insulin resistance in diabetics; obtain humans, administer modulator of insulin resistance, monitor human response to insulin |
| 04/26/2005 | US6884574 Methods of identifying agents which inhibit GPR-9-6 |
| 04/26/2005 | US6884425 Adapted for improving skin ageing and/or photoageing signs, which cutaneous signs are directly a result of a chronic micro-inflammatory process induced by repeated UV exposures |
| 04/26/2005 | US6884421 Butyric acid, wheat fibre bran and guar gum |
| 04/26/2005 | US6884420 Antidiabetic agents contains Agaricus blazeii, alpha lipoic acid, transfer factor, polymannose, fenugreek, coenzyme Q-10, selenium, zinc, vitamin C, vitamin E, chromium and vanadium |
| 04/26/2005 | US6884408 Delivery of diphenhydramine through an inhalation route |
| 04/26/2005 | CA2125251C A pharmaceutical composition for angiotensin ii-mediated diseases |
| 04/21/2005 | WO2005035726A2 Multi-layered polymerizing hydrogels for tissue regeneration |
| 04/21/2005 | WO2005035534A1 Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same |
| 04/21/2005 | WO2005035525A2 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 04/21/2005 | WO2005035516A1 Novel fused heterocyclic compound and use thereof |
| 04/21/2005 | WO2005035514A2 Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| 04/21/2005 | WO2005035477A1 Method of stabilizing compound having quinone skeleton and stabilized composition |
| 04/21/2005 | WO2005034998A2 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 04/21/2005 | WO2005034991A1 Improved protocol for enhancing immunization through adoptive transfer of dendritic cells |
| 04/21/2005 | WO2005034979A2 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 04/21/2005 | WO2005034967A1 Pharmaceutical or cosmetic compositions for treating skin |
| 04/21/2005 | WO2005034966A1 Use of xenon with hypothermia for treating neonatal asphyxia |
| 04/21/2005 | WO2005034965A1 Use of hyaluronic acid for treating sprain and strain |
| 04/21/2005 | WO2005034962A1 Methods and means for modulating lipid metabolism |
| 04/21/2005 | WO2005034945A1 Use of norphenazone and coenzyme q for curing arthrose, arthritis and osteoarthritis |
| 04/21/2005 | WO2005034934A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir) |
| 04/21/2005 | WO2005034929A2 Tissue remodeling and vascularization |
| 04/21/2005 | WO2005034920A1 A solid dosage form comprising a fibrate |
| 04/21/2005 | WO2005034908A2 A solid dosage form comprising a fibrate and a statin |
| 04/21/2005 | WO2005034883A2 A method of healing skin wounds in mammals and a composition therefor |
| 04/21/2005 | WO2005034875A2 Method and material for enhance tissue-biomaterial integration |
| 04/21/2005 | WO2005034728A2 Colon cleansing composition and method |
| 04/21/2005 | WO2005020882A3 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 04/21/2005 | WO2005000208A3 Combination therapy for the treatment of neoplasms |
| 04/21/2005 | WO2004108119A3 Use of atp or derivatives in medicine |
| 04/21/2005 | WO2004093995A3 Use of antioxidants to treat bone loss disorders |
| 04/21/2005 | WO2004091593A3 Methods for the treatment of pain comprising opioid antagonists |
| 04/21/2005 | WO2004089288A3 Method of treating lower urinary tract disorders |
| 04/21/2005 | WO2004028455A3 Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 04/21/2005 | WO2003096970A3 Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency |
| 04/21/2005 | WO2003061584A3 Novel substituted benzimidazole dosage forms and method of using same |
| 04/21/2005 | WO2003049673A3 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 04/21/2005 | WO2003048349A8 Acetoacetyl-coa thiolase and use of for the identification of novel fungicidal substances |
| 04/21/2005 | WO2002099053A3 Slc22as as modifiers of the p53 pathway and methods of use |
| 04/21/2005 | WO2002057425A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 04/21/2005 | US20050086711 Transgenic animals and methods for screening for anti-amyloidogenic agents and agents for treating neurodegenerative disease |
| 04/21/2005 | US20050085711 Method and system for leading macromolecule substances into living target cells |
| 04/21/2005 | US20050085652 Trans configuration; reacting 3-methyl butyric acid with halvaleric acid; forming 8-methyl-6-nonynoic acid; reduction; activation; acylation |
| 04/21/2005 | US20050085637 Pyrimidine compounds |